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MEDICAL REVIEW
Antifungal Resistance in Yeast Vaginitis
Erica Duna
School ofEpidemiology and Public Health, Yale University, New Haven, Connecticut
The increased number ofvaginal yeast infections in the pastfew years has been a disturbing trend,
andthe scientific community has been searchingforits etiology. Several theories have beenputforth
to explain the apparent increase. First, the recent widespread availability of low-dosage, azole-
based, over-the-counter antifungal medicationsfor vaginal yeast infections encourages women to
self-diagnose and treat, and women may be misdiagnosing themselves. Their vaginitis may be
caused by bacteria, parasites or may be a symptom ofanother underlying health condition. As a
result, they may be unnecessarily and chronically expose themselves to antifungal medications and
encouragefungal resistance. Second, medical technology has increased the life span ofseriously
immune compromised individuals, yetthese individuals arefrequentlyplaguedby opportunisticfun-
gal infections. Long-term and intense azole-based antifungal treatment has been linked to an
increase in resistant Candida andnon-Candida species. Thus, thefuture oflimiting antifungal resis-
tance lies in identifying thefactorspromoting resistance and implementingpolicies toprevent it.
DEFINITION OFTHE PROBLEM
Vaginal yeast infections are an unfor-
tunate but common problem among
women. It is estimated that 13 million
cases are reported annually in the United
States [1]. Three out of four women will
experience at least one yeast infection dur-
ing theirreproductive years, and about half
will have recurrent infections [2]. In recent
years, the number of vaginal yeast infec-
tions has been dramatically increasing. In
fact, not only has there been an increase in
the number ofvaginal yeast infections, but
the number of fungal infections, in gener-
al, is on the rise. Coinciding with the
increase in fungal infections is the
increased use of new and old antifungal
therapies. Antifungal medications have
appeared on drugstore shelves, available
without a prescription. Among the most
visible and highly advertised antifungal
medications are cures for vaginal yeast
infections. It is believed that the wide-
spread availability of these antifungals,
which formerly required a prescription,
has contributed to an environment con-
ducive to breeding antifungal resistance.
Women are now more likely to self-
medicate when symptoms ofitching, burn-
ing, irritation, and vaginal discharge arise.
Single-celled eukaryotic yeastofthe genus
Candida are the primary perpetrators of
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yeast infections or vulvovaginal candidia-
sis. Macroscopically, Candida develop
into smooth, soft, white/cream-colored
colonies with an unmistakable beer-like
odor [3]. Overgrowth of Candida in the
vagina produces localized symptoms of
itching, burning, and irritation. Abnormal
discharge characterized by a cottage-
cheese-like consistency may occur.
However, discharge, irritation, and painful
urination are also the symptoms ofseveral
other types of vaginitis. Bacteria are the
most common cause of vaginitis.
Trichomoniasis or "trich," a sexually
transmitted disease, is another leading
cause. It is produced by a single-celled
proto parasite called Trichomonas vagi-
nalis. Diagnosing the true cause ofvagini-
tis from the clinical presentation is diffi-
cult because there are several organisms
that produce similar symptoms
Vulvovaginal candidiasis can be clin-
ically differentiated vaginal secretions for
evidence of yeast forms. Visualization of
yeast can be performed by clinicians
through three quick diagnostic methods:
10 percent KOH, saline wet mount, or
Gram stain [4]. Without clinical confirma-
tion ofthe etiology, women may automat-
ically dismiss vaginitis as a fungal infec-
tion and begin an antifungal regiment. Of
course, antifungals are ineffective in com-
bating vaginitis caused by bacteria or par-
asites. And women may unnecessarily
expose themselves to multiple over-the-
counter (OTC) medications before seek-
ing professional help.
Some women first attempt to cure
yeast infections with do-it-yourself treat-
ments and natural remedies before turning
to OTC antifungal preparations. Yogurt is
the most popular choice and commonly
recommended by medical professionals.
Adding yogurt to the vagina is believed to
increase the number of Lactobacillus aci-
dophilus bacterium. These bacteria are
part of the natural flora of the vagina and
produce hydrogen peroxide, which kills
yeast, keeping its growth in check.
Applying garlic, teatree oil, and boric acid
to the affected areas are other common
home remedies. Many women report suc-
cess with these treatments. In fact, the
efficacy ofsome ofthese natural remedies
has been scientifically tested. The success-
ful use of boric acid vaginal capsules to
treat persistent vaginitis caused by C.
glabrata was reported in women who had
previously failed several courses of azole
treatments [5].
Nevertheless, the overwhelmingly
preferred treatment to fight yeast infec-
tions are the OTC, azole-based antifungal
medications. The azoles, which include
imidazoles and triazoles, function by
inhibiting ergosterol biosynthesis through
the selective inhibition of fungal
cytochrome P450 14-a-demethylase
(P45014adm)- Without methylation of the
sterol molecule during its synthesis, the
sterol molecule cannot orient correctly
within the phospholipid bilayer. As a
result, fungal membrane fluidity and sta-
bility is disrupted, and the cell dies [6].
Azoles are fungistatic drugs. In other
words, they inhibit further proliferation of
yeast but do not destroy yeast cells per se.
They are the preferred course oftreatment
for localized Candida infections, and they
usually effectively cure vulvovaginal can-
didasis.
For the most advanced cases of
Candidasis, the antifungal treatment
regime includes amphotericin B (amp B)
and/or flucytosine (5-fluorocytosine).
Amp B is a broadspectrum, antifungal
drug that is extremely effective in control-
ling systemic fungal infections. Amp B
and nystatin, both polyene compounds,
are fungicidal drugs that bind to fungal
sterols, causing perturbations in the cell
membrane. Weakening the membrane
makes the fungal cells leaky and results in
electrolyte imbalance and cell death. Amp
B effectively eliminates fungal infections,
and the prevalence of amp B-resistant
strains is very low. However, polyene
drugs, especially amp B, have several sig-
nificant limitations, such as the necessity
for intravenous use, a broad range oftoxi-
cities, including fever, chills, nausea,
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Table 1. Classes of antifungal drugs.
Class Compounds Mechanism Uses
Polyene Amphotericin B Binds to sterols causing Systemic disease
Nystatin pertubations in cell Topical disease
membrane (fungitoxic)
Azole Clotrimazole Inhibits ergosterol Topical disease




Pyrimidine Fluorocytosine (5-FC) Inhibits DNA and Systemic disease
RNA synthesis
nephrotoxcity [7]. Patients treated for seri-
ous fungal infections with lengthy regi-
mens of amp B may lose function of their
kidneys. Flucytosine or 5-FC, an inhibitor
offungal RNAsynthesis, has similar toxic
side effects.
Since the introduction of azole anti-
fungals, this regimen has become the pre-
ferred to treat Candida infections, because
azole therapy results in fewer side-effects
and seems to eliminate fungi almost as
well as or as well as amphotericin therapy.
A multicenter, prospective study compar-
ing the efficacy offluconazole versus amp
B on the morbidity and mortality of
patients with candidemia, indicated that
fluconazole was as effective as ampho-
tericin in the treatment of systemic
Candida infection. In addition, flucona-
zole had significantly fewer side effects
(12 percent) compared with amp B (44
percent) [8].
Azole therapy is certainly more
attractive than amp B in terms of its side-
effects, butthere is a serious concern about
promoting resistance through its continued
use. In C. albicans, fluconazole resistance
is well documented and appears to occur
inherently in approximately 2 percent to 5
percent of isolates. In vivo resistance has
been observed during long-term or repeat-
ed courses ofazole antifungal drugs [9].
Until recently, the issue of antifungal
resistance has received little attention.
More efforts have been placed on the phe-
nomenon of antibiotic resistance. The
mechanisms by which bacteria and yeast
develop resistance are different. Fungi do
not have the ability to transfer resistance
genes between separate yeast cells.
Nevertheless, mycotic resistance has
become as widespread aproblem as antibi-
otic resistance. The increased number of
drug-resistant fungal infections has
prompted questions about its etiology. One
causal factorthat warrants study is the role




Candida is a normal part ofthe muco-
cutaneous and alimentary tract flora and
lives in dynamic equilibrium with bacteria
and other microorganisms. Normally, it is
localized to the mouth, throat, skin, scalp,
vagina, fingers, nails, bronchi, lungs, and
gastrointestinal tract. Aside from vulvo-
vaginal candidiasis, oral candidiasis or
oral thrush is a common disease affecting
infants. Because infants have underdevel-
oped immune systems, they are especially
vulnerable to fungal infections such as oral
thrush or diaper rash. Other superficial284 Dun: Antifungal resistance in yeast vaginitis
fungal infections include athlete's foot,
jock itch, or dermal mycosis. Candida is
an opportunistic fungi and rarely dissemi-
nates into serious systemic infections such
as septicemia, endocarditis, and meningi-
tis unless there is some underlying
immunological dysfunction.
Within the human body, there are sev-
eral nonspecific mechanisms by which
fungal proliferation is controlled.
Transferrins, the human iron binding pro-
teins in the blood, deprive microbes of the
iron they need for making respiratory
enzymes. n-globulins also found in the
serum cause a nonimmunological clump-
ing of Candida and facilitate their elimina-
tion by inflammatory cells. Phagocytosis
by neutrophils is the primary mechanism
that prevents the establishment of fungal
infections. Fungi that are too large to be
ingested by phages may be killed through
immuniological mechanisms. Both cellular
and humoral responses are evoked.
Antibodies attach to the fungi, and phago-
cytic cells secrete lethal lysosomal
enzymes into the fungi. Prolonged resis-
tance to fungal disease is mainly mediated
by T-lymphocytes. Clinical observations
indicate that people with depressed
immune systems are especially prone to
invasive and systemic fungal infections
[10].
In the late 1980s, several key studies
indicated that 40 percent ofpatients dying
from nosoncomial infections were dying
as a result of invasive fungal infections.
Though there have been advances in drug
therapy, opportunistic fungal infections
are preying upon the growing number of
people who are immune-compromised -
people with AIDS, cancer patients, organ
transplant patients, severe burn victims, as
well as infants and the elderly [11]. The
group at highest risk for acquiring fungal
infections are AIDS patients. In 1988,
approximately 58 percent of AIDS cases
were associated with a mycotic infection
[12]. Among the different infections,
oropharyngeal candidiasis is the most
common. A study conducted in 1997
showed that 90 percent of AIDS patients
suffered from oropharyngeal or esopha-
geal candidosis at some time during their
illness [13]. An estimated 5 to 10 percent
ofpatients in the advanced stages ofAIDS
have recurrent infections that are difficult
to treat. It is believed thatprolonged use of
antifungal azole agents may result in the
selection of azole-resistant organisms.
Already, antifungal resistance to flucona-
zole is apparent in this population.
However, there are few alternatives for
preventing invasive fungal infections
other than antifungal prophylaxis with flu-
conazole.
At the same time, the use of weaker
azoles like miconazole and clotrimazole,
found in OTC antifungal preparations
used to treat vaginal yeast infections are
also believed to contribute to the emer-
gence of resistant Candida species. Since
OTC azoles are used by a larger popula-
tion, higher rates of azole resistance is a
serious concern. An additional complica-
tion is that Candida may not only be resis-
tant to OTC azoles but also cross-resis-
tance to the stronger azoles like flucona-
zole and its second generation derivative,
voriconazole. Spread of these cross-resis-
tant strains would render ineffective these
last-resort drugs that are needed to deal
with more serious invasive infections.
EXISTING LITERATURE ON
ANTIFUNGAL RESISTANCE
Much of the research performed on
antifungal resistance has focused on the
molecularmechanisms offungal cell resis-
tance. Studying the mechanisms by which
fungi express resistance is essential in the
development ofnew drugs thattarget these
pathways. Three main ways fungal cells
elude the toxic effects of antifungals are
presently known: manipulation ofkey fun-
gal sterol enzymes, over-expression ofkey
fungal sterol enzymes, and drug-resistant
pumps. The primary mechanism of drug
resistance is the presence ofdrug-resistant
efflux pumps that may expel a single drug
or multiple types of drugs (multi-drug
resistant pumps). Multi-drug resistantDun: Antifungal resistance in yeast vaginitis 285
pumps may explain the phenomenon of
cross-resistance observed among the fam-
ily of azole compounds.
Several studies have assessed the
changing epidemiology of candidemia.
The subject populations have generally
included groups with underlying immuno-
logical deficits such as AIDS, cancer, or
diabetes. These groups are especially
prone to fungal infections, and the mor-
bidity and mortality by fungal infections is
significantly higher than in the general
population. In a multi-center, randomized,
double-blind, placebo-controlled trial, the
efficacy offluconazole prophylaxis on the
vaginal flora of HIV-positive women was
examined. The study found that women
who had taken fluconazole prophylaxis
had areduction in C. albicans colonization
but an increase in the odds of being colo-
nized with a non-albicans species, primar-
ily C. glabrata. It illustrated the shift to
non-albicans species that tend to show
resistance to azole-based drugs [14]. A
study on bone marrow transplant patients
who received fluconazole prophylaxis
indicated a correlation between antifungal
therapy and in increased incidence of C.
krusei. Patients who received antifungals
had a seven-fold greater frequency of C.
krusei infection, and the C. krusei were
determined to be resistant to fluconazole
in vitro [15].
Patterns of resistance in immune-
compromised groups have been extensive-
ly examined in the fungal literature.
However, few studies have examined the
prevalence of azole resistance in the gen-
eral public or among a healthy population.
Future studies might address the develop-
ment of resistance in well populations as
more people are employing antifungal pro-
phylaxis without confirmed diagnosis of
fungal infection.
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